Skip to search formSkip to main contentSkip to account menu

Mabthera

National Institutes of Health

Related topics

Related topics

2 relations
Rituxan

Broader (1)

rituximab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Interference of therapeutic monoclonal immunoglobulins in the investigation of M-proteins
2011
2011
Biosimilars encircle Rituxan, US debates innovator exclusivity
2008
2008
Acute tumor lysis syndrome after rituximab administration in Burkitt’s lymphoma
Bienvenu J, 2001, Hematol J, V2, P378, DOI 10.1038-sj.thj.6200133; Cairo MS, 2004, BRIT J HAEMATOL, V127, P3, DOI 10.1111-j.1365… 
2006
2006
MabThera (Rituximab) Plus Cyclophosphamide, Vincristine and Prednisone (CVP) Chemotherapy Improves Survival in Previously Untreated Patients with Advanced Follicular Non-Hodgkin’s Lymphoma (NHL).
Design/methods: Rituximab added to 8 cycles of CVP (R-CVP) chemotherapy improves time to progression and duration of response in… 
2006
2006
Traitement par rituximab d’un purpura thrombopénique immunologique au cours d’un lupus systémique
2005
2005
Treatment results of CHOP-21, CHOEP-21, MACOP-B and PMitCEBO with and without rituximab in young good-prognosis patients with aggressive lymphomas: Rituximab as an “equalizer” in the MInT (MABTHERA…
6529 Background: The addition of rituximab (R) to 6 cycles of CHOP-like regimens in the MInT trial significantly improved overall… 
Highly Cited
2003
Highly Cited
2003
Treatment of resistant pemphigus vulgaris with an anti‐CD20 monoclonal antibody (Rituximab)
Summary We describe a 54‐year‐old man with resistant pemphigus vulgaris. Standard therapies had afforded inadequate control and… 
2002
2002
Recurrent coiled-coil motifs in NUP98 fusion partners provide a clue to leukemogenesis.
The NUP98 gene is the target of recurrent translocations in leukemia that fuse the 5′ portion of NUP98 with coding sequence from… 
Highly Cited
2001
Highly Cited
2001
Complement Activation in Circulation and Central Nervous System after Rituximab (Anti-CD20) Treatment of B-Cell Lymphoma
Rituximab (IDEC-C2B8, Mabthera®, Rituxan®), a chimeric monoclonal antibody against the B-cell specific CD20-antigen, has been… 
Review
2000
Review
2000
Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens.
BACKGROUND In view of the successful use of serotherapy in many B-cell malignancies, we and others have sought to identify tumor… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)